Updates on the Treatment of Erythrodermic Psoriasis

References

• Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655–662. doi:10.1016/j.jaad.2009.05.048
   PubMed Web of Science ®Google Scholar
• Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21(5 Pt 1):985–991. doi:10.1016/S0190-9622(89)70287-5
   PubMed Web of Science ®Google Scholar
• Yan D, Afifi L, Jeon C, Cordoro KM, Liao W. A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol Online J. 2018;24(7):13030/qt5z21q4k2.
   Google Scholar
• Chen HS, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese psoriatic patients in a single clinic. Dermatol Sinica. 2003;21(3):216–224.
   Google Scholar
• Stinco G, Errichetti E. Erythrodermic psoriasis: current and future role of biologicals. BioDrugs. 2015;29(2):91–101. doi:10.1007/s40259-015-0119-4
   PubMed Web of Science ®Google Scholar
• Lo Y, Chiu HY, Tsai TF. Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic. Mol Diagn Ther. 2020;24(1):85–93. doi:10.1007/s40291-019-00441-x
   PubMed Web of Science ®Google Scholar
• Zhang P, Chen H, Duan Y, et al. Analysis of Th1/Th2 response pattern for erythrodermic psoriasis. J Huazhong Univ Sci Tech Med Sci. 2014;34(4):596–601. doi:10.1007/s11596-014-1322-0
   PubMedGoogle Scholar
• Li L-F, Sujan SA, Yang H, Wang W-H. Serum immunoglobulins in psoriatic erythroderma. Clin Exp Dermatol. 2005;30(2):125–127. doi:10.1111/j.1365-2230.2004.01717.x
   PubMed Web of Science ®Google Scholar
• Deeva I, Mariani S, De Luca C, et al. Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. Cytokine. 2010;49(2):163–170. doi:10.1016/j.cyto.2009.09.014
   PubMed Web of Science ®Google Scholar
• Groves RW, Kapahi P, Barker JN, Haskard DO, MacDonald DM. Detection of circulating adhesion molecules in erythrodermic skin disease. J Am Acad Dermatol. 1995;32(1):32–36.
   Web of Science ®Google Scholar
• Moy AP, Murali M, Kroshinsky D, Duncan LM, Nazarian RM. Immunologic Overlap of Helper T-Cell Subtypes 17 and 22 in Erythrodermic Psoriasis and Atopic Dermatitis. JAMA Dermatol. 2015;151(7):753–760. doi:10.1001/jamadermatol.2015.2
   PubMed Web of Science ®Google Scholar
• Wang H, Wang S, Li L, et al. Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis. Cytokine. 2020;138:155391. doi:10.1016/j.cyto.2020.155391
   PubMed Web of Science ®Google Scholar
• Zheng J, Gao Y, Liu N, et al. Higher prevalence of thyroid dysfunction in patients with erythrodermic psoriasis. J Dermatol. 2020;47(9):1007–1012. doi:10.1111/1346-8138.15427
   Web of Science ®Google Scholar
• Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854–862. doi:10.1111/bjd.16083
   PubMed Web of Science ®Google Scholar
• Henseler T, Koch F, Westphal E. Presence of HLA- DR7 in type I psoriasis. J Invest Dermatol. 1992;98(4):607.
   Web of Science ®Google Scholar
• Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143(6):1177–1182. doi:10.1046/j.1365-2133.2000.03885.x
   PubMed Web of Science ®Google Scholar
• Signa S, Campione E, Rusmini M, et al. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. Pediatr Rheumatol Online J. 2019;17(1):38. doi:10.1186/s12969-019-0336-3
   PubMed Web of Science ®Google Scholar
• Collins P, Rogers S. The efficacy of methotrexate in psoriasis–a review of 40 cases. Clin Exp Dermatol. 1992;17(4):257–260. doi:10.1111/j.1365-2230.1992.tb02161.x
   PubMed Web of Science ®Google Scholar
• Van Dooren-greebe RJ, Kuijpers AL, Mulder J, De Boo T. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol. 1994;130(2):204–210. doi:10.1111/j.1365-2133.1994.tb02901.x
   Web of Science ®Google Scholar
• Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14(5):382–388. doi:10.1046/j.1468-3083.2000.00058.x
   PubMed Web of Science ®Google Scholar
• Kumar B, Dhar S, Handa S, Kaur I. Methotrexate in childhood psoriasis. Pediatr Dermatol. 1994;11(3):271–273. doi:10.1111/j.1525-1470.1994.tb00602.x
   PubMed Web of Science ®Google Scholar
• Aydin F, Canturk T, Senturk N, Turanli AY. Methotrexate and ciclosporin combination for the treatment of severe psoriasis. Clin Exp Dermatol. 2006;31(4):520–524. doi:10.1111/j.1365-2230.2006.02153.x
   PubMed Web of Science ®Google Scholar
• Khaled A, Ben Hamida M, Zeglaoui F, Kharfi M, Ezzine N, Fazaa B. Traitement du psoriasis par méthotrexate à l’ère des biothérapies: étude chez 21 patients tunisiens [Treatment of psoriasis by methotrexate in the era of biotherapies: a study in 21 Tunisian patients]. Therapie. 2012;67(1):49–52. doi:10.2515/therapie/2012004
   Web of Science ®Google Scholar
• Hawilo A, Zaraa I, Benmously R, et al. Erythrodermic psoriasis: epidemiological clinical and therapeutic features about 60 cases. Tunis Med. 2011;89(11):841–847.
   Google Scholar
• Mahmood T, Zaghi D, Menter A. Emerging oral drugs for psoriasis. Expert Opin Emerg Drugs. 2015;20(2):209–220. doi:10.1517/14728214.2015.1010509
   PubMed Web of Science ®Google Scholar
• Lim KK, Su WP, Schroeter AL, Sabers CJ, Abraham RT, Pittelkow MR. Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clin Proc. 1996;71(12):1182–1191. doi:10.4065/71.12.1182
   Web of Science ®Google Scholar
• Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Management of erythrodermic psoriasis with low-dose cyclosporine. Dermatology. 1993;187(Suppl 1):30–37. doi:10.1159/000247289
   Web of Science ®Google Scholar
• Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis. Int J Immunopathol Pharmacol. 2009;22(1):235–238. doi:10.1177/039463200902200126
   PubMed Web of Science ®Google Scholar
• Ahdout J, Mandel H, Chiu M. Erythroderma in a patient taking acitretin for plaque psoriasis. J Drugs Dermatol. 2008;7(4):391–394.
   Web of Science ®Google Scholar
• Sprecher E, Bergman R, Friedman-Birnbaum R. Cyclosporine treatment of psoriatic erythroderma complicated by bacterial sepsis. J Eur Acad Dermatol Venereol. 1999;12(2):197–198. doi:10.1111/j.1468-3083.1999.tb01027.x
   Web of Science ®Google Scholar
• Borghi A, Corazza M, Mantovani L, Bertoldi AM, Giari S, Virgili A. Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients. Int J Dermatol. 2012;51(12):1512–1516. doi:10.1111/j.1365-4632.2012.05571.x
   Web of Science ®Google Scholar
• Prossick TA, Belsito DV. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. Cutis. 2006;78(3):178–180.
   PubMed Web of Science ®Google Scholar
• Brechtel B, Wellenreuther U, Toppe E, Czarnetski BM. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. J Am Acad Dermatol. 1994;30(6):1023–1024. doi:10.1016/S0190-9622(09)80147-3
   Web of Science ®Google Scholar
• Kokelj F, Plozzer C, Torsello P, Trevisan G. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports). J Eur Acad Dermatol Venereol. 1998;11(2):177–179.
   PubMed Web of Science ®Google Scholar
• Korstanje MJ, Bessems PJ. Combination therapy ciclosporin-etretinate effective in erythrodermic psoriasis. Dermatologica. 1989;179(2):94. doi:10.1159/000248324
   Google Scholar
• Franchi C, Cainelli G, Frigerio E, Garutti C, Altomare GF. Association of cyclosporine and 311 nM UVB in the treatment of moderate to severe forms of psoriasis: a new strategic approach. Int J Immunopathol Pharmacol. 2004;17(3):401–406. doi:10.1177/039463200401700321
   PubMed Web of Science ®Google Scholar
• Charbit L, Mahé E, Phan A, et al. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children. Br J Dermatol. 2016;174(5):1118–1121. doi:10.1111/bjd.14326
   PubMed Web of Science ®Google Scholar
• Kuijpers ALA, van Dooren-greebe RJ. Failure of combination therapy with acitretin and cyclosporine A in 3 patients with erythrodermic psoriasis. Dermatology. 1997;194(1):88–90. doi:10.1159/000246070
   PubMed Web of Science ®Google Scholar
• Rao S, Bernshteyn M, Sohal R, Proumen R, Goodman A, Shepherd Z. The Management of Erythrodermic Psoriasis Complicated by Cyclosporine. Case Rep Dermatol Med. 2020;2020:5215478. doi:10.1155/2020/5215478
   PubMedGoogle Scholar
• Kim BS, Shin KS, Youn JI, Lee YS. Treatment of erythrodermic psoriasis with etretinate. Ann Dermatol. 1991;3(2):107–111. doi:10.5021/ad.1991.3.2.107
   Google Scholar
• Rosińska D, Wolska H, Jablonska S, Konca I. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5(4):266. doi:10.1111/j.1525-1470.1988.tb00902.x
   PubMed Web of Science ®Google Scholar
• Tuyp E, MacKie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acad Dermatol. 1986;14(1):70–73. doi:10.1016/S0190-9622(86)70009-1
   Web of Science ®Google Scholar
• Roeder C. Psoriatic erythroderma and bullous pemphigoid treated successfully with acitretin and azathioprine. Eur J Dermatol. 1999;9(7):537–539.
   Web of Science ®Google Scholar
• Takahashi MDF, Castro LG, Romiti R. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol. 2007;157(4):828–831. doi:10.1111/j.1365-2133.2007.08111.x
   PubMed Web of Science ®Google Scholar
• Ahdout J, Mandel H, Chiu M. Erythroderma in a patient taking acitretin for plaque psoriasis. J Drugs Dermatol. 2008;7:391.
   Web of Science ®Google Scholar
• Ling MR. Acitretin: optimal dosing strategies. J Am Acad Dermatol. 1999;41(3 Pt 2):S13–17. doi:10.1016/S0190-9622(99)70360-9
   Web of Science ®Google Scholar
• Valenzuela F, Fernández J, Sánchez M, Zamudio A. Erythrodermic psoriasis and human immunodeficiency virus: association and therapeutic challenges. An Bras Dermatol. 2018;93(3):438–440. doi:10.1590/abd1806-4841.20187387
   Web of Science ®Google Scholar
• Geilen CC, Tebbe B, Garcia Bartels C, Krengel S, Orfanos CE. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol. 1998;138(6):1101–1102. doi:10.1046/j.1365-2133.1998.02296.x
   Web of Science ®Google Scholar
• Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006;155(1):156–159. doi:10.1111/j.1365-2133.2006.07217.x
   PubMed Web of Science ®Google Scholar
• Pique-Duran E, Perez-Cejudo JA. Psoriatic erythroderma treated with etanercept. Actas Dermosifiliogr. 2007;98(7):508–510.
   Google Scholar
• Romero-Maté A, García-Donoso C, Martinez-Morán C, Hernández-Núñez A, Borbujo J. Long-term management of erythrodermic psoriasis with anti-TNF agents. Dermatol Online J. 2010;16(6):15.
   PubMedGoogle Scholar
• Viguier M, Pagès C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol. 2012;167(2):417–423. doi:10.1111/j.1365-2133.2012.10940.x
   PubMed Web of Science ®Google Scholar
• Sahel H, Bouadjar B. Treatment of Erythrodermic Psoriasis with Infliximab and Etanercept in Two Cases. J Clinic Exper Cosme Derma. 2017;1:002.
   Google Scholar
• Fraga NA, Paim Mde F, Follador I, Ramos AN, Rêgo VR. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept. An Bras Dermatol. 2011;86(4 suppl 1):S144–S147. doi:10.1590/S0365-05962011000700038
   PubMed Web of Science ®Google Scholar
• Poulalhon N, Begon E, Lebbe C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156(2):329–336. doi:10.1111/j.1365-2133.2006.07639.x
   PubMed Web of Science ®Google Scholar
• Lisby S, Gniadecki R. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venereol. 2004;84(3):247–248.
   PubMed Web of Science ®Google Scholar
• Heikkila H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005;141(12):1607–1610. doi:10.1001/archderm.141.12.1607
   PubMedGoogle Scholar
• Mahé E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol. 2003;149(1):170–173. doi:10.1046/j.1365-2133.2003.05384.x
   Web of Science ®Google Scholar
• Rongioletti F, Borenstein M, Kirsner R, Kerdel F. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatol Treat. 2003;14(4):222–225. doi:10.1080/09546630310010895
   Google Scholar
• Torii H, Nakagawa H, Japanese Infliximab Study Investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38(4):321–334. doi:10.1111/j.1346-8138.2010.00971.x
   PubMed Web of Science ®Google Scholar
• Lewis TG, Tuchinda C, Lim HW, Wong HK. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. J Drugs Dermatol. 2006;5(6):546–548.
   Google Scholar
• O’Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol. 2002;138(5):644–648. doi:10.1001/archderm.138.5.644
   Google Scholar
• Fiehn C, Andrassy K. Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Dis. 2004;63(3):232. doi:10.1136/ard.2003.014191
   Web of Science ®Google Scholar
• Yip L, Harrison S, Foley P. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis. Australas J Dermatol. 2008;49(3):152–155. doi:10.1111/j.1440-0960.2008.00463.x
   Web of Science ®Google Scholar
• Tridico LA, Antonio JR, Mathias CE, Pozetti EMO. Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis. An Bras Dermatol. 2017;92(5):743–745. doi:10.1590/abd1806-4841.20176565
   Web of Science ®Google Scholar
• Valdés A, Mdel P, Schroeder HF, Roizen GV, Honeyman MJ, Sánchez ML. Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade). Rev Med Chil. 2006;134(3):326–331. doi:10.4067/s0034-98872006000300009
   Web of Science ®Google Scholar
• Kurokawa R, Hagiwara A, Niijima Y, Kojima K. Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: a case report. Radiol Case Rep. 2018;13(2):460–463. doi:10.1016/j.radcr.2018.02.005
   PubMedGoogle Scholar
• Belinchon I, Lucas A, Ballester I, Betlloch I, Pérez-Crespo M. Successful treatment of life threatening erythrodermic psoriasis with infliximab. J Am Acad Dermatol. 2009;60(3):AB171.
   Web of Science ®Google Scholar
• Suárez Pedreira I, Santos Juanes J, Caminal Montero L, Trapiella L. Infliximab: an alternative in refractory erythrodermic psoriasis. Piel. 2006;21(6):317–318. doi:10.1016/S0213-9251(06)72498-4
   Google Scholar
• Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: a systematic review. J Am Acad Dermatol. 2020;83(1):151–158. doi:10.1016/j.jaad.2020.03.073
   PubMed Web of Science ®Google Scholar
• Lee WK, Kim GW, Cho HH, et al. Erythrodermic psoriasis treated with golimumab: a case report. Ann Dermatol. 2015;27(4):446–449. doi:10.5021/ad.2015.27.4.446
   PubMed Web of Science ®Google Scholar
• Mumoli N, Vitale J, Gambaccini L, Sabatini S, Brondi B, Cei M. Erythrodermic psoriasis. QJM. 2014;107(4):315. doi:10.1093/qjmed/hct139
   PubMed Web of Science ®Google Scholar
• Richetta AG, Maiani E, Carlomagno V, et al. Treatment of erythrodermic psoriasis in HCV+patient with adalimumab. Dermatol Ther. 2009;22(Suppl 1):S16–18. doi:10.1111/j.1529-8019.2009.01266.x
   PubMed Web of Science ®Google Scholar
• Nowsheen S, Kohorst JJ, El-Azhary RA. Adalimumab-induced erythrodermic reactions. Int J Dermatol. 2019;58(10):e204–e206. doi:10.1111/ijd.14503
   PubMed Web of Science ®Google Scholar
• Pescitelli L, Dini V, Gisondi P, et al. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis. J Dermatol Sci. 2015;78(2):149–151. doi:10.1016/j.jdermsci.2015.01.005
   PubMed Web of Science ®Google Scholar
• Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol. 2010;162(5):1144–1146. doi:10.1111/j.1365-2133.2010.09669.x
   PubMed Web of Science ®Google Scholar
• Wang TS, Tsai TF. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol. 2011;38(11):1096–1099. doi:10.1111/j.1346-8138.2011.01224.x
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim HJ, Lee S, Park YL. Erythrodermic psoriasis improved by ustekinumab: a report of two cases. Ann Dermatol. 2016;28(1):121–122. doi:10.5021/ad.2016.28.1.121
   PubMed Web of Science ®Google Scholar
• Koutsoukou XA, Papadavid E, Theodoropoulos K, Rigopoulos D. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission. Dermatol Ther. 2014;27(5):257–259. doi:10.1111/dth.12131
   PubMed Web of Science ®Google Scholar
• Stinco G, Piccirillo A, Errichetti E, Bergamo S, Patrone P. Treatment of recalcitrant erythrodermic psoriasis with ustekinumab. Eur J Dermatol. 2014;24(3):387–390. doi:10.1684/ejd.2014.2325
   PubMed Web of Science ®Google Scholar
• Saraceno R, Talamonti M, Galluzzo M, Chiricozzi A, Costanzo A, Chimenti S. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. Case Rep Dermatol. 2013;5(3):254–259. doi:10.1159/000348645
   PubMedGoogle Scholar
• Castineiras I, Fernandez-Diaz L, Juarez Y, Lueiro M. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol. 2012;39(8):730–731. doi:10.1111/j.1346-8138.2011.01499.x
   PubMed Web of Science ®Google Scholar
• Buggiani G, D’Erme AM, Krysenka A, Pescitelli L, Lotti T, Prignano F. Efficacy of ustekinumab in sub-erythrodermic psoriasis: when TNF-blockers fail. Dermatol Ther. 2012;25(3):283–285. doi:10.1111/j.1529-8019.2012.01465.x
   PubMed Web of Science ®Google Scholar
• Castiñeiras I, Fernández-Diaz L, Juárez Y, Lueiro M. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies. J Dermatol. 2012;39(8):730–731.
   PubMed Web of Science ®Google Scholar
• Concha-Garzón MJ, Godoy-Trapero A, Daudén E, et al. Short- and long-term treatment of erythrodermic psoriasis with ustekinumab: a national and multicenter case series. J Am Acad Dermatol. 2014;70(5):AB189.
   Web of Science ®Google Scholar
• Errichetti E, Piccirillo A. Latent tuberculosis reactivation in a patient with erythrodermic psoriasis under treatment with ustekinumab and a low dose steroid, despite isoniazid chemoprophylaxis. Eur J Dermatol. 2014;24(4):508–509. doi:10.1684/ejd.2014.2386
   PubMed Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539. doi:10.1111/1346-8138.14294
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Camela E, Fabbrocini G, Marasca C. A case of erythrodermic psoriasis successfully treated with guselkumab. Dermatol Ther. 2020;33(2):e13238.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Tsai TF. Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab. Dermatol Ther (Heidelb). 2021;11(1):301–306. doi:10.1007/s13555-020-00480-x
   PubMed Web of Science ®Google Scholar
• Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis. Clin Pharmacokinet. 2020;59(5):575–589. doi:10.1007/s40262-019-00829-2
   PubMed Web of Science ®Google Scholar
• Weng HJ, Wang TS, Tsai TF. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series. Br J Dermatol. 2018;178(6):1439–1440. doi:10.1111/bjd.16252
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Lappi A, Pau M, Murgia S, Rongioletti F. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol. 2017;31(9):e420–e421.
   PubMed Web of Science ®Google Scholar
• Mateu-Puchades A, Santos-Alarcón S, Martorell-Calatayud A, Pujol-Marco C, Sánchez-Carazo JL. Erythrodermic psoriasis and secukinumab: our clinical experience. Dermatol Ther. 2018;31(4):e12607. doi:10.1111/dth.12607
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Campione E, Mazzilli S, Bianchi L, Talamonti M. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. J Dermatolog Treat. 2018;29(sup1):1–11. doi:10.1080/09546634.2018.1524818
   Web of Science ®Google Scholar
• Rongioletti F, Mugheddu C, Murgia S. Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis. JAAD Case Rep. 2018;4(5):486–488. doi:10.1016/j.jdcr.2018.01.006
   PubMedGoogle Scholar
• Dogra S, Bishnoi A, Narang T, Handa S. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis. Dermatol Ther. 2018;31(4):e12611. doi:10.1111/dth.12611
   PubMed Web of Science ®Google Scholar
• Tichy M. Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab. Postepy Dermatol Alergol. 2019;36(4):495–497. doi:10.5114/ada.2019.87454
   PubMed Web of Science ®Google Scholar
• Damiani G, Pacifico A, Russo F, et al. Use of secukinumab in a cohort of erythrodermic psoriatic patients: a pilot study. J Clin Med. 2019;8(6):770. doi:10.3390/jcm8060770
   PubMed Web of Science ®Google Scholar
• Shibata T, Muto J, Takama H, Yanagishita T, Ito T, Watanabe D. Case of psoriatic erythroderma induced by the discontinuation of the chronic use of topical steroid after dialysis initiation and successfully treated with secukinumab. J Dermatol. 2019;46(4):e119–20. doi:10.1111/1346-8138.14649
   Web of Science ®Google Scholar
• Pizzatti L, Mugheddu C, Sanna S, Atzori L, Rongioletti F. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab. Dermatol Ther. 2020;33(3):e13348. doi:10.1111/dth.13348
   PubMed Web of Science ®Google Scholar
• Liu LC, Jin XH, Sun C, Xia JX. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature. Dermatol Ther. 2021;34:e14825. doi:10.1111/dth.14825
   Web of Science ®Google Scholar
• Japanese Ixekizumab Study Group, Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362. doi:10.1111/1346-8138.13622
   Web of Science ®Google Scholar
• Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol. 2019;33(2):325–332. doi:10.1111/jdv.15287
   PubMed Web of Science ®Google Scholar
• Megna M, Gallo L, Balato N, Balato A. A case of erythrodermic psoriasis successfully treated with ixekizumab. Dermatol Ther. 2019;32(2):e12825. doi:10.1111/dth.12825
   PubMed Web of Science ®Google Scholar
• Trovato E, Orsini C, Russo F, Cortonesi G, Rubegni P. Ixekizumab as treatment of erythrodermic psoriasis. Dermatol Ther. 2021;34:e14868. doi:10.1111/dth.14868
   Web of Science ®Google Scholar
• Pangilinan MCG, Sermswan P, Asawanonda P. Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis. Case Rep Dermatol. 2020;12(2):132–137. doi:10.1159/000508781
   PubMed Web of Science ®Google Scholar
• Lo Y, Tsai TF. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series. Br J Dermatol. 2019;181(5):1106–1107. doi:10.1111/bjd.18174
   PubMed Web of Science ®Google Scholar
• Lo Y, Huang YH, Tsai TF. Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with history of chronic erythrodermic psoriasis who failed prior secukinumab: a bicentric retrospective study. Dermatol Sinica. 2021.
   Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52‐week, open‐label study. Br J Dermatol. 2017;176(3):741–751. doi:10.1111/bjd.14702
   PubMed Web of Science ®Google Scholar
• Bernardini N, Skroza N, Tolino E, et al. Recurrent erythrodermic psoriasis and polycythemia successfully treated with brodalumab. Dermatol Ther. 2020;33(6):e14338. doi:10.1111/dth.14338
   PubMed Web of Science ®Google Scholar
• Megna M, Fabbrocini G, Ferrillo M, Cinelli E. Erythrodermic psoriasis successfully and rapidly treated with brodalumab: report of two cases. Dermatol Ther. 2020;33(6):e14351. doi:10.1111/dth.14351
   PubMed Web of Science ®Google Scholar
• Papadavid E, Kokkalis G, Polyderas G, Theodoropoulos K, Rigopoulos D. Rapid clearance of erythrodermic psoriasis with apremilast. J Dermatol Case Rep. 2017;11(2):29–31. doi:10.3315/jdcr.2017.1246
   Web of Science ®Google Scholar
• Krishnamoorthy G, Kotecha A, Pimentel J. Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy. BMJ Case Rep. 2019;12(1):e226959. doi:10.1136/bcr-2018-226959
   Google Scholar
• Arcilla J, Joe D, Kim J, Kim Y, Truong VN, Jaipaul N. Erythrodermic psoriasis treated with apremilast. Dermatol Rep. 2016;8(1):6599. doi:10.4081/dr.2016.6599
   Google Scholar
• Mugheddu C, Pizzatti L, Sanna S, Atzori L, Rongioletti F. COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management. J Eur Acad Dermatol Venereol. 2020;34(8):e376–e378. doi:10.1111/jdv.16625
   Web of Science ®Google Scholar
• Megna M, Fabbrocini G, Camela E, Cinelli E. Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period. J Eur Acad Dermatol Venereol. 2020;34(11):e705–e707. doi:10.1111/jdv.16443
   PubMed Web of Science ®Google Scholar
• Beltran Monasterio EP. Low-dose Naltrexone: an Alternative Treatment for Erythrodermic Psoriasis. Cureus. 2019;11(1):e3943. doi:10.7759/cureus.3943
   Web of Science ®Google Scholar
• Nishizawa A, Satoh T, Yokozeki H. Erythrodermic psoriasis improved by panitumumab, but not bevacizumab. Acta Derm Venereol. 2012;92(4):360–361. doi:10.2340/00015555-1348
   PubMed Web of Science ®Google Scholar
• Kharaeva Z, Gostova E, De Luca C, Raskovic D, Korkina L. Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition. 2009;25(3):295–302. doi:10.1016/j.nut.2008.08.015
   PubMed Web of Science ®Google Scholar
• Gregoire ARF, DeRuyter BK, Stratman EJ. Psoriasis Flares Following Systemic Glucocorticoid Exposure in Patients With a History of Psoriasis. JAMA Dermatol. 2021;157(2):198–201. doi:10.1001/jamadermatol.2020.4219
   Web of Science ®Google Scholar
• Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol. 2013;27(8):1022–1025. doi:10.1111/j.1468-3083.2012.04656.x
   Web of Science ®Google Scholar
• Cretu S, Salavastru CM, Tiplica GS. Treatment of psoriatic erythroderma using systemic corticosteroids: a timeless option? Dermatol Ther. 2020;33(6):e14222. doi:10.1111/dth.14222
   Web of Science ®Google Scholar
• Pang ML, Murase JE, Koo J. An updated review of acitretin–a systemic retinoid for the treatment of psoriasis. Expert Opin Drug Metab Toxicol. 2008;4(7):953–964. doi:10.1517/17425255.4.7.953
   PubMed Web of Science ®Google Scholar
• van der Vleuten CJ, Gerritsen MJ, Steijlen PM, de Jong EM. A therapeutic approach to erythrodermic psoriasis: report of a case and a discussion of therapeutic options. Acta Derm Venereol. 1996;76(1):65–67. doi:10.2340/00015555766567
   Web of Science ®Google Scholar
• Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ. A systematic review of treatment strategies for erythrodermic psoriasis. J Dermatolog Treat. 2021;32(1):49–55. doi:10.1080/09546634.2019.1689228
   PubMed Web of Science ®Google Scholar
• Shao S, Wang G, Maverakis E, Gudjonsson JE. Targeted Treatment for Erythrodermic Psoriasis: rationale and Recent Advances. Drugs. 2020;80(6):525–534. doi:10.1007/s40265-020-01283-2
   PubMed Web of Science ®Google Scholar
• Hsu SH, Tsai TF. Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis. Expert Rev Clin Pharmacol. 2020;13(3):211–232. doi:10.1080/17512433.2020.1743175
   PubMed Web of Science ®Google Scholar
• Li X, Andersen KM, Chang HY, Curtis JR, Alexander GC. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020;79(2):285–291. doi:10.1136/annrheumdis-2019-216102
   PubMed Web of Science ®Google Scholar
• Ger TY, Huang YH, Hui RC, Tsai TF, Chiu HY. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis. 2019;10:2040622319843756. doi:10.1177/2040622319843756
   Web of Science ®Google Scholar
• Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493–503. doi:10.1080/17512433.2020.1767590
   PubMed Web of Science ®Google Scholar
• Huang YW, Tsai TF. Efficacy of tofacitinib in patients with moderate-to-severe psoriasis who had inadequate responses to prior biologics. Dermatol Sinica. 2019;37(4):205–208.
   Web of Science ®Google Scholar